Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Rahma received his medical degree from University of Damascus in 1998. He completed his residency in Internal Medicine at East Carolina University followed by Geriatrics Fellowship at University of Hawaii. Dr. Rahma joined the National Cancer Institute (NCI) as an Immunotherapy Research Fellow in the Vaccine Branch in 2009 and completed a Fellowship in Medical Oncology in 2013 specializing in Cancer Immunotherapy and Gastrointestinal (GI) Oncology. Prior to joining Dana-Farber Cancer Institute, Dr. Rahma was the co-leader of the Hepatobiliary and Pancreatic Cancer Program at University of Virginia where he led translational research efforts as the Principal Investigator of many clinical trials.Dr. Rahma is currently a Principal Investigator at the Center for Immuno-Oncology and Gastroenterology Cancer Center at Dana-Farber Cancer Institute. His research focus is on drug development of combinational immune therapeutics with the goal of moving immunotherapy to GI cancers and understanding the resistance mechanism to immunotherapy in GI cancers. He is currently the national lead of many studies combining immune checkpoint inhibitors and standard of care including chemotherapy and radiation therapy in addition to many novel combinations. Dr. Rahma also leads the Immune Toxicity Work Group at Dana-Farber, a unique program that is devoted to mitigating immune related toxicities.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions